Kuano

Kuano combines quantum mechanics and AI to design targeted enzyme inhibitors.

Cambridge, UK—Founded 2020—Website

£2.8MTotal raised

Kuano is a drug discovery enterprise that merges quantum mechanics with artificial intelligence to engineer next-generation medicines targeting enzymes. Based in Cambridge, the firm develops simulation platforms to model enzyme behaviour for precision drug design.

Founders

Vid Stojevic

Co-founder and CEO

Vid is the co-founder and chief executive of Kuano, following previous co-founding and technical leadership roles at GTN. His background includes academic research positions at University College London, the University of Gent, and the University of Vienna.

David Wright

Co-founder

Parminder Ruprah

Co-founder

Jarryl D’Oyley

Co-founder